Intra Cellular Therapies reported $-55629000 in EBIT for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Acadia Pharmaceuticals ACAD:US USD -30866000 2.78M
ALKERMES ALKS:US USD -60641000 26.18M
Aptinyx Inc APTX:US USD -14657000 2.45M
Biocryst Pharmaceuticals BCRX:US USD -17445000 17.28M
Biogen BIIB:US USD 872.1M 68.8M
Bristol Myers Squibb BMY:US USD 2.74B 461M
Cytokinetics CYTK:US USD -108441000 97.57M
Esperion Therapeutics ESPR:US USD -41623000 10.75M
Gilead Sciences GILD:US USD 2.84B 808M
Halozyme Therapeutics HALO:US USD 83.69M 49.63M
Intra Cellular Therapies ITCI:US USD -55629000 32.29M
Johnson & Johnson JNJ:US USD 6.27B 572M
Marinus Pharmaceuticals MRNS:US USD -30099000 6.67M
Minerva Neurosciences NERV:US USD -5207150 1.76M
Nektar Therapeutics NKTR:US USD -37471000 10.24M
Neurocrine Biosciences NBIX:US USD 87.8M 33.1M
Prothena PRTA:US USD -50332000 7.12M
United Therapeutics UTHR:US USD 314.3M 112.5M